Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

Bosutinib, an orally active, Src/Abl tyrosine kinase inhibitor, has demonstrated clinical activity and acceptable tolerability in chronic phase chronic myeloid leukemia (CP CML). This updated analysis of the BELA trial assessed the safety profile and management of toxicities of bosutinib versus imat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Gambacorti-Passerini, Carlo, Cortes, Jorge E, Lipton, Jeff H, Dmoszynska, Anna, Wong, Raymond S, Rossiev, Victor, Pavlov, Dmitri, Gogat Marchant, Karin, Duvillié, Ladan, Khattry, Navin, Kantarjian, Hagop M, Brümmendorf, Tim H
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4305212/
https://ncbi.nlm.nih.gov/pubmed/24944159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23788
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados